US Orphan Drug Market To Surpass USD 60 Billion by 2018

With factors like government support, high profitability and many more, this market is expected to grow at CAGR of 5%.

Release Date: 31-Jul-2014



“US Orphan Drug Market Outlook 2018 Research Report Highlights:

In the largest market for orphan drugs, USA, there was a shortage of adequate therapies for treating many rare diseases. These therapies were not developed as companies did not expect these drugs to be highly profitable. Hence there was a lack of interest and thus investment on the part of pharma companies in the USA. Therefore, the FDA introduced incentives for developing such drugs. This step taken by the FDA was successful in creating a thriving market for orphan drugs.  

It was in the USA first that a special law exclusively for governing orphan drugs was framed in the form of the Orphan Drug Act of 1983. This led to an increase in the popularity of orphan drugs. The FDA also has been continuously increasing its efforts to support this market by providing significant financial and non-financial incentives to the pharmaceutical companies to attract them. This has been one of the major drivers of growth for the US orphan drugs market.

For Report Sample Visit: US Orphan Drug Market Outlook 2018

Or Contact: avinash@kuickresearch.com

Need custom market research solution? We can help you with that too.